Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 12:58 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 361–384 of 704 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: CC5013 Clear all

Conditions: Multiple Myeloma
Interventions: Teclistamab, Daratumumab, Lenalidomide, Dexamethasone, Talquetamab; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years and older
Enrollment: 1,590 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2033
U.S. locations: 67
States / cities: Gilbert, Arizona • Tucson, Arizona • Clovis, California + 53 more

Conditions: Multiple Myeloma
Interventions: Dara-VRd intensification, Dara-R maintenance, AHCT intensification, Dara-R maintenance, AHCT intensification, Tec-Dara consolidation, Tec-Dara maintenance, AHCT intensification, Dara-R consolidation, Dara-R maintenance, Dara-VRd induction; Drug
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 18 Years and older
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2029
U.S. locations: 10
States / cities: Birmingham, Alabama • Denver, Colorado • New York, New York + 7 more

Conditions: Relapsed/Refractory Follicular Lymphoma, Relapsed/Refractory Marginal Zone Lymphoma (R/R MZL)
Interventions: Odronextamab, Lenalidomide, Rituximab; Drug
Lead sponsor: Regeneron Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 580 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2031
U.S. locations: 9
States / cities: Los Angeles, California • Plantation, Florida • Indianapolis, Indiana + 6 more

Conditions: Multiple Myeloma
Interventions: Elranatamab, Elotuzumab, Pomalidomide, Dexamethasone, Bortezomib, Carfilzomib; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 492 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 98
States / cities: Mobile, Alabama • Beverly Hills, California • Clovis, California + 53 more

Conditions: Graft-versus-Host Disease
Interventions: Lenalidomide; Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2011
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adult Acute Myeloid Leukemia With Del(5q), Adult Acute Myeloid Leukemia With Inv(16)(p13;q22), Adult Acute Myeloid Leukemia With t(15;17)(q22;q12), Adult Acute Myeloid Leukemia With t(16;16)(p13;q22), Adult Acute Myeloid Leukemia With t(8;21)(q22;q22), Recurrent Adult Acute Myeloid Leukemia
Interventions: cytarabine, lenalidomide; Drug
Lead sponsor: Roswell Park Cancer Institute; Other
Eligibility: 18 Years and older
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2019
U.S. locations: 1
States / cities: Buffalo, New York

Conditions: Lymphoma, Large B-Cell, Diffuse
Interventions: lenalidomide, Placebo, Rituximab, Cyclophosphamide, Doxorubicin, prednisone, vincristine; Drug
Lead sponsor: Celgene; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 570 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2022
U.S. locations: 22
States / cities: Fayetteville, Arkansas • Orange, California • Sacramento, California + 16 more

Conditions: Plasma Cell Leukemia
Interventions: Bortezomib, Daratumumab, Dexamethasone, Lenalidomide, Pegylated Liposomal Doxorubicin Hydrochloride; Drug · Biological
Lead sponsor: City of Hope Medical Center; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 5
States / cities: Duarte, California • Rochester, Minnesota • St Louis, Missouri + 2 more

Conditions: Multiple Myeloma, Post-transplant MRD-guided Maintenance Therapy, Pre-transplant Purging
Interventions: Elranatamab, Lenalidomide, Plerixafor, Melphalan, Busulfan, G-CSF, Stem cell transplant; Drug · Procedure
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years to 75 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2031
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Primary Central Nervous System Lymphoma (PCNSL), Secondary Central Nervous System Lymphoma (SCNSL)
Interventions: Ibrutinib, Lenalidomide, Rituximab; Drug
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2026
U.S. locations: 7
States / cities: Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more

Conditions: Lymphoid Leukemia, Small Lymphocytic Lymphoma, Lymphoma, Non-Hodgkin
Interventions: Bendamustine, Rituximab, Lenalidomide; Drug
Lead sponsor: University of Wisconsin, Madison; Other
Eligibility: 18 Years and older
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2022
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Multiple Myeloma
Interventions: lenalidomide (Revlimid®), Cyclophosphamide, Prednisone; Drug
Lead sponsor: Attaya Suvannasankha; Other
Eligibility: 18 Years and older
Enrollment: 70 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2014
U.S. locations: 1
States / cities: Indianapolis, Indiana

Conditions: Glioblastoma, Gliosarcoma, Malignant Gliomas
Interventions: lenalidomide, Radiation; Drug · Radiation
Lead sponsor: Dana-Farber Cancer Institute; Other
Eligibility: 18 Years and older
Enrollment: 23 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2009
U.S. locations: 4
States / cities: Boston, Massachusetts • Charlottesville, Virginia

Conditions: Carcinoma, Non-Small-Cell Lung
Interventions: Lenalidomide; Drug
Lead sponsor: Jun Zhang; Other
Eligibility: 18 Years and older
Enrollment: 7 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Multiple Myeloma
Interventions: Lenalidomide; Drug
Lead sponsor: National Heart, Lung, and Blood Institute (NHLBI); NIH
Eligibility: 18 Years to 70 Years
Enrollment: 273 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2019
U.S. locations: 42
States / cities: Tucson, Arizona • Duarte, California • La Jolla, California + 37 more

Conditions: Ann Arbor Stage II Diffuse Large B-Cell Lymphoma, Ann Arbor Stage III Diffuse Large B-Cell Lymphoma, Ann Arbor Stage IV Diffuse Large B-Cell Lymphoma
Interventions: Cyclophosphamide, Doxorubicin Hydrochloride, Laboratory Biomarker Analysis, Lenalidomide, Prednisone, Rituximab, Vincristine Sulfate; Drug · Other · Biological
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 349 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2026
U.S. locations: 502
States / cities: Anchorage, Alaska • Scottsdale, Arizona • Tucson, Arizona + 349 more

Conditions: Chronic Lymphocytic Leukemia, CLL, Untreated, Front-line, First-Line, Initial Therapy
Interventions: Lenalidomide and Rituximab; Drug
Lead sponsor: Chronic Lymphocytic Leukemia Research Consortium; Network
Eligibility: Not listed
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2011
U.S. locations: 5
States / cities: La Jolla, California • Boston, Massachusetts • New Hyde Park, New York + 2 more

Conditions: Stage I Multiple Myeloma, Stage II Multiple Myeloma, Stage III Multiple Myeloma
Interventions: bortezomib, lenalidomide, dexamethasone; Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 48 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2014
U.S. locations: 275
States / cities: Scottsdale, Arizona • Fairfield, California • San Diego, California + 184 more

Conditions: Prostate Cancer
Interventions: Lenalidomide, Docetaxel, Prednisone, Placebo; Drug
Lead sponsor: Celgene; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 1,059 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2016
U.S. locations: 66
States / cities: Phoenix, Arizona • Sedona, Arizona • Tucson, Arizona + 61 more

Conditions: Smoldering Plasma Cell Myeloma
Interventions: Biopsy Specimen Radiography, Lenalidomide, Vaccine Therapy; Procedure · Drug · Biological
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2025
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Solid Organ Malignancies, Adenoidcystic Carcinoma, Neuroendocrine Tumors
Interventions: Lenalidomide, Everolimus; Drug
Lead sponsor: Emory University; Other
Eligibility: 18 Years and older
Enrollment: 44 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2020
U.S. locations: 2
States / cities: Atlanta, Georgia

Conditions: Renal Cell Carcinoma
Interventions: Lenalidomide, Sunitinib; Drug
Lead sponsor: Celgene; Industry
Eligibility: 18 Years and older
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2011
U.S. locations: 3
States / cities: Ann Arbor, Michigan • Cleveland, Ohio • Nashville, Tennessee

Conditions: Multiple Myeloma
Interventions: Elotuzumab, Lenalidomide, Dexamethasone, Bortezomib; Drug
Lead sponsor: University of Arkansas; Other
Eligibility: 18 Years to 75 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 1
States / cities: Little Rock, Arkansas

Conditions: Lymphoma, Large B-Cell, Diffuse
Interventions: CC-122, CC-223, Rituximab, CC-292; Drug
Lead sponsor: Celgene; Industry
Eligibility: 18 Years and older
Enrollment: 174 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2023
U.S. locations: 8
States / cities: Stanford, California • New Haven, Connecticut • Tampa, Florida + 5 more

Search by objective public record fields.

A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma

Sequential Therapy in Multiple Myeloma Guided by MRD Assessments

A Trial to Find Out if Odronextamab Combined With Lenalidomide is Safe and Works Better Than Rituximab Combined With Lenalidomide in Adult Participants With Follicular Lymphoma and Marginal Zone Lymphoma

MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide)

Lenalidomide (Revlimid®) as Second Line Therapy in Patients With Chronic Graft-Vs-Host Disease (GVHD)

Lenalidomide and Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia

Efficacy and Safety Study of Lenalidomide Plus R-CHOP Chemotherapy Versus Placebo Plus R-CHOP Chemotherapy in Untreated ABC Type Diffuse Large B-cell Lymphoma

Daratumumab, Bortezomib, Dexamethasone, Pegylated Liposomal Doxorubicin Hydrochloride, and Lenalidomide in Treating Participants With Plasma Cell Leukemia

Pre-transplant Purging and Post-transplant MRD-guided Maintenance Therapy With Elranatamab in Patients With High-risk Multiple Myeloma

Ibrutinib With Rituximab and Lenalidomide for Patients With Recurrent/Refractory Primary or Secondary Central Nervous System Lymphoma (PCNSL/SCNSL)

Bendamustine and Rituximab Induction Therapy and Maintenance Rituximab and Lenalidomide in Previously Untreated CLL/SLL

Phase II Study of Revlimid®, Oral Cyclophosphamide and Prednisone for Patients With Newly Diagnosed Multiple Myeloma

Study of Lenalidomide and XRT in Patients With Newly Diagnosed Glioblastoma Multiforme

Lenalidomide Maintenance Therapy in Stage IIIB/IV Non-small Cell Lung Cancer

Continued, Long-Term Follow-Up and Lenalidomide Maintenance Therapy for Patients on BMT CTN 0702 Protocol (BMT CTN 07LT)

Rituximab and Combination Chemotherapy With or Without Lenalidomide in Treating Patients With Newly Diagnosed Stage II-IV Diffuse Large B Cell Lymphoma

Multi-center Trial of Revlimid® and Rituximab, for First-Line Treatment of Chronic Lymphocytic Leukemia (CLL)

Bortezomib and Dexamethasone With or Without Lenalidomide in Treating Patients With Multiple Myeloma Previously Treated With Dexamethasone

Study to Evaluate Safety and Effectiveness of Lenalidomide in Combination With Docetaxel and Prednisone for Patients With Castrate-Resistant Prostate Cancer

Personalized Vaccine in Treating Patients With Smoldering Multiple Myeloma

Study of Everolimus (RAD001) in Combination With Lenalidomide

Study of Lenalidomide in Combination With Sunitinib to Evaluate the Safety and Efficacy in Patients With Renal Cell Carcinoma

2017-03: A Single-Arm, Open-label Study of Anti-Signaling Lymphocytic Activation Molecule F7 (Anti-SLAMF7) Monoclonal Antibody (mAb) Therapy After Autologous Stem Cell Transplant in Patients With Multiple Myeloma

Novel Combinations of CC-122, CC-223, CC-292, and Rituximab in Diffuse Large B-cell Lymphoma and Follicular Lymphoma